Table 2.
Clinical characteristics of de novo psoriasis associated with dupilumaba
| Characteristics | |
|---|---|
| Gender | n = 35 |
| Male | 19 (54.3%) |
| Female | 16 (45.7%) |
| Age, years, mean (range) | 48.6 (22–92) |
| Time to onset, months, mean (range) | n = 34b |
| 4.3 (1–18) | |
| Lesion types | n = 35 |
| Plaque psoriasis | 27 (77.1%) |
| Pustular psoriasis | 3 (8.6%) |
| Guttate psoriasis | 2 (5.7%) |
| Erythrodermic psoriasis | 1 (2.9%) |
| Reverse psoriasis | 1 (2.9%) |
| Sebopsoriasis | 1 (2.9%) |
| Lesion location | |
| Extremities | 27 (77.1%) |
| Trunk | 13 (37.1%) |
| Scalp | 11 (31.4%) |
| Face and neck | 4 (11.4%) |
| Nail | 2 (5.7%) |
| Dupilumab discontinuation | n = 33 |
| 16 (48.5%) | |
| Management | n = 32 |
| Topical treatment | |
| Topical corticosteroids | 27 (84.4%) |
| Topical vitamin D derivatives | 6 (18.8%) |
| Topical calcineurin inhibitors | 2 (6.3%) |
| Phototherapy | |
| NB-UVB | 2 (6.3%) |
| Conventional systemic treatments | |
| Oral corticosteroids | 4 (12.5%) |
| Cyclosporine | 2 (6.3%) |
| Mycophenolate mofetil | 1 (3.1%) |
| JAK inhibitors | |
| Delgocitinib ointment | 2 (6.3%) |
| Upadacitinib | 1 (3.1%) |
| Outcome | n = 30 |
| Improvement | 28 (93.3%) |
| Insufficient remission or recurrence | 2 (6.7%) |
aCase reports of pediatric patients and flare of preexistent psoriasis are not summarized in table due to the small sample size, and detailed information can be found in Table 1.
bOne case is excluded for a long onset time of 30 months.